"Humans and other mammals"@en . "Benoxaprofenum"@en . . "(1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid"@en . "withdrawn"@en . . . . . "The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions. The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982."@en . . . " "@en . . . . . . . . "2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid"@en . "2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid"@en . . . . . . . . . . . . . . . . . . "Evans, D., Dunwell, D.W. and Hicks, A.; US. Patent 3,912, 18; October 14, 1975; assigned to Lilly Industries Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; U.S. Patent 3,962,441; June 8, 1976; assigned to Lilly Industries, Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; US. Patent 3,962,452; June 8, 1976; assigned to Lilly Industries, Ltd."@en . "Benoxaprofene"@en . . "51234-28-7"@en . "2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid"@en . "Benoxaprofen"@en . . "DL-benoxaprofen"@en . . "Benoxaprofeno"@en . . .